Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia

Ilan J N Koppen1, Frederik J R Hermans, Gertjan J L Kaspers

  • 1Department of Paediatric Oncology/Haematology, VU University Medical Center, Amsterdam, The Netherlands.

Insights

Genetic variations in folate metabolism may affect childhood acute lymphoblastic leukaemia (ALL) risk. Certain MTHFR gene polymorphisms appear to decrease ALL susceptibility in non-Asian populations.

Area of Science:

  • Genetics
  • Oncology
  • Epidemiology

Background:

  • Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer.
  • Genetic factors, including folate-related gene polymorphisms, may influence ALL susceptibility.

Purpose of the Study:

  • To review and synthesize findings from studies investigating the association between folate-related gene polymorphisms and ALL susceptibility.
  • To identify specific polymorphisms and populations where associations are most evident.

Main Methods:

  • Systematic review of 14 quality-assessed studies.
  • Analysis of data from 729 children and 1821 non-age-defined patients.
  • Comparison of results across different ethnic populations (Asian vs. European).

Main Results:

  • Polymorphisms in the MTHFR gene (677C>T and 1298A>C) may be associated with decreased ALL susceptibility in non-Asian populations.
  • Associations with other folate-related genes (MTRR, MTR, TYMS, SLC19A1, NNMT, SHMT1) were less clear and supported by limited studies.
  • Study results sometimes contradicted, potentially due to population differences.

Conclusions:

  • Constitutional differences in folate gene polymorphisms partly explain susceptibility to childhood ALL.
  • Further research is needed to clarify the role of various folate gene polymorphisms in ALL susceptibility, especially in diverse populations.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life